The Founder: A Mission Born from Necessity

---

Founder & CEO, NomosLogic Inc.
Salt Lake City, Utah

Matt Hardy is the founder and CEO of NomosLogic, where he is building the first clinical genomics infrastructure that bridges consumer DNA data, real-time clinical decision support, and multi-omic analysis into a single platform. Under his technical leadership, NomosLogic has mapped over 1.26 million clinical rules across 497,000 proprietary genomic nomenclature translations, delivering variant classification and pharmacogenomic guidance in under 30 seconds — against an industry standard measured in days.

Matt is a systems architect with three decades of experience building high-performance platforms. At NomosLogic, he designed the core engine stack: COVENANT for genome resolution, TRINITY for multi-omic fusion integrating genomic, biomarker, and clinical data, Hardy Bridge for cross-nomenclature translation, and PROTEUS for evolutionary drug resistance simulation. The company has filed nine patent applications through Wilson Sonsini.

His work is personal. Matt is Patient MH-001 — the first clinical case study validated on the NomosLogic platform. Analysis of his own eight-year-old consumer DNA file identified a compound heterozygous TPMT variant that contraindicates an entire class of chemotherapy drugs, and a CFTR variant associated with a 5.7x increased risk of gastrointestinal cancer. An independent, blinded endoscopy subsequently confirmed colonic polyps and duodenal pathology consistent with the platform's predictions. The platform found what the healthcare system had missed for years — and the findings were confirmed by a physician who had never seen the genomic data.

Matt's mission is to make that experience available to the more than 100 million people worldwide who already have consumer DNA files sitting unused. NomosLogic's consumer bridge allows individuals to upload existing DNA data and receive clinical-grade reports covering drug interactions, disease risk, and biomarker correlations — then seamlessly connect that data to their healthcare providers through a cryptographic identity layer that preserves patient sovereignty and consent.

He is building NomosLogic to become the foundational infrastructure for precision medicine: a platform where researchers model drug resistance in real time, clinicians receive genomic intelligence at the point of prescribing, health plans stratify population risk before adverse events occur, and every patient has access to the same standard of genomic analysis regardless of where they receive care.